Raloxifene improves the ovariectomy-induced impairment in endothelium-dependent vasodilation

Menopause

Volumn 14, Issue 4, 2007, Pages 656-661

  Takahashi, Kazuhiro ^a   Mori Abe, Akiko ^a   Takata, Keiko ^a   Ohta, Tsuyoshi ^a   Kawagoe, Jun ^a   Tsutsumi, Seiji ^a   Ohmichi, Masahide ^b   Kurachi, Hirohisa ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Flow mediated dilatation; Menopause; Ovariectomy; Raloxifene

Indexed keywords

ISOSORBIDE DINITRATE; RALOXIFENE;

ADULT; ARTERY BLOOD FLOW; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAM; ENDOTHELIAL DYSFUNCTION; FEMALE; GYNECOLOGIC SURGERY; HEART SOUND; HUMAN; MENOPAUSE; OVARIECTOMY; POSTOPERATIVE CARE; PULSE WAVE; TREATMENT OUTCOME; VASODILATATION;

ADULT; ANKLE; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; OVARIECTOMY; PULSATILE FLOW; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; VASODILATION;

EID: 34447344060     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000248704.30204.33     Document Type: Article

References (43)

1. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-646.
2. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990;81:1680-1687.
3. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762.
4. Chen SJ, Li H, Durand J, Oparil S, Chen YF. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996;93:577-584.
5. Takahashi K, Ohmichi M, Yoshida M, et al. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol 2003;178:319-329.
6. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
7. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538-541.
8. Hisamoto K, Ohmichi M, Kurachi H, et al. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem 2001;276:3459-3467.
9. Hisamoto K, Ohmichi M, Kanda Y, et al. Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J Biol Chem 2001;276:47642-47649.
10. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
11. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;250:H1145-H1149.
12. Sagach VF, Tkachenko MN. On the mechanism of the involvement of endothelium in reactive hyperemia. Experientia 1991;47:828-830.
13. Perregaux D, Chaudhuri A, Mohanty P, et al. Effect of gender differences and estrogen replacement therapy on vascular reactivity. Metabolism 1999;48:227-232.
14. Ohmichi M, Kanda Y, Hisamoto K, et al. Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas 2003;44:125-131.
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
16. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
17. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001;104:1773-1778.
18. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
19. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-1451.
20. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-2197.
21. Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001;21:1512-1519.
22. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-629.
23. Kibbe M, Billiar T, Tzeng E. Inducible nitric oxide synthase and vascular injury. Cardiovasc Res 1999;43:650-657.
24. Wassmann S, Laufs U, Stamenkovic D, et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002;105:2083-2091.
25. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999;100:1095-1101.
26. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 2003;88:2135-2140.
27. Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL. Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol 2003;188:304-309.
28. Duschek EJ, Stehouwer CD, de Valk-de Roo GW, Schalkwijk CG, Lambert J, Netelenbos C. Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women. J Intern Med 2003;254:85-94.
29. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 2003;42:698-704.
30. Ceresini G, Marchini L, Rebecchi I, et al. Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women. Atherosclerosis 2003;167:121-127.
31. Cagnacci A, Paoletti AM, Zanni A, et al. Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women. J Clin Endocrinol Metab 2002;87:4117-4121.
32. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998;97:2494-2498.
33. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994;24:471-476.
34. Herrington DM, Espeland MA, Crouse JR III, et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol 2001;21:1955-1961.
35. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999;43:985-991.
36. Sanada M, Taguchi A, Higashi Y, et al. Forearm endothelial function and bone mineral loss in postmenopausal women. Atherosclerosis 2004;176:387-392.
37. Hashimoto M, Akishita M, Eto M, et al. Modulation of endothelium- dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 1995;92:3431-3435.
38. Williams MR, Westerman RA, Kingwell BA, et al. Variations in endothelial function and arterial compliance during the menstrual cycle. J Clin Endocrinol Metab 2001;86:5389-5395.
39. Sitges M, Heras M, Roig E, et al. Acute and mid-term combined hormone replacement therapy improves endothelial function in postmenopausal women with angina and angiographically normal coronary arteries. Eur Heart J 2001;22:2116-2124.
40. Al-Khalili F, Eriksson M, Landgren BM, Schenck-Gustafsson K. Effect of conjugated estrogen on peripheral flow-mediated vasodilation in postmenopausal women. Am J Cardiol 1998;82:215-218.
41. Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL. Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol 2003;188:304-309.
42. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-2439.
43. da Costa LS, de Oliveira MA, Rubim VS, et al. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am J Cardiol 2004;94:1453-1456.